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In our Select pages, we highlight exciting themes that have emerged from our review of the recent literature on
a particular topic. In this issue, we present Neurobiology Select in which we discuss a cluster of recent papers
that increases our understanding of complex human neurological disorders such as schizophrenia, Tourette’s
syndrome, and developmental dyslexia. Some of the genes implicated in the etiology of these diseases encode
proteins that regulate neuronal morphology. There is also evidence that microRNAs (miRNAs) may contribute to
the regulation of neuronal morphology and possibly to disease.
A Candidate Gene for Tourette’s Syndrome
Mutations in a human gene called SLITRK1 are associated with Tourette’s syndrome, a disorder characterized by
motor tics and vocal outbursts. SLITRK1 is related to Slit protein family members that repel growing axons through
interactions with Robo axon guidance receptors. In their new work, State and colleagues (Abelson et al., 2005) first
identifiedSLITRK1 based on its proximity to a chromosomal inversion breakpoint in an individual with Tourette’s syn-
drome. They then sequenced this gene in 174 individuals with a family history of Tourette’s. They found one family
where several affected members carried a frameshift mutation in SLITRK1 leading to premature truncation of the
protein and loss of function. The authors show that overexpression of SLITRK1 in cultured cortical neurons boosts
the length of dendrites, whereas overexpression of SLITRK1 carrying the frameshift mutation does not. It is not yet
clear how a reduction inSLITRK1 and the resulting altered dendritic morphology might result in Tourette’s syndrome.
Next, the investigators found in two unrelated individuals with Tourette’s a rare sequence variant (var321) located
in the 30 untranslated region (30UTR) of SLITRK1 transcripts at a putative binding site for an miRNA (miR-189). The
sequence variant replaces a G:U wobble pair ‘‘mismatch’’ between theSLITRK1 transcript and the miRNA with a per-
fect A:U match, which enhances binding. It is known that miRNAs can repress gene expression by binding to 30UTR
regions. Predictably, in a neuronal cell line, miRNA-189 repressed expression of a luciferase transgene bearing the
wild-type 30 UTR of SLITRK1. Luciferase transgene expression was further repressed when the 30UTR carrying
var321 was used, which the authors suggest is due to enhanced binding of miRNA-189 to SLITRK1.
Could the finding that SLITRK1 is associated with Tourette’s syndrome lead to a new animal model for this dis-
order? A mouse deficient in SLITRK1 has not yet been generated, although mouse neurons do express SLITRK1.
It remains to be seen whether mice with reduced expression of SLITRK1 develop motor tics or other behavioral ab-
normalities reminiscent of Tourette’s syndrome in humans. Such an animal model could help to determine whether
aberrant axon outgrowth, altered dendritic morphology, or loss of trophic signaling contribute to Tourette’s syndrome.
Abelson et al. (2005). Science 310, 317-320.
An miRNA Promotes Neurite Outgrowth
A second study reveals another example where miRNAs may be involved in the regula-
tion of neuronal morphology (Vo et al., 2005). Vo and colleagues identify an miRNA, in-
duced by neurotrophins (factors that promote neuronal survival), that stimulates neurite
outgrowth. In an earlier genome-wide screen for genes regulated by the transcription fac-
tor CREB, these investigators identified the gene encoding miR-132 as a potential target
of CREB. In the new work, they confirm that miR-132 is regulated by CREB and that the
neurotrophin BDNF stimulates transcription of the miR-132 gene. The authors identify
p250GAP, a GTPase-activating protein that inactivates Rac and cdc42, as a target of
miR-132. They propose that downregulation of p250GAP expression by miR-132 in neu-
rons leads to an increase in the number of neurites. The studies by Abelson et al. (2005)
and Vo et al. (2005) raise the possibility that dysregulation of miRNA function may in some
way contribute to human neurological disease.
Vo et al. (2005). PNAS 102, 16426-16431.
A Transcription Factor Controls Translation in
Axonal Growth Cones
Another mechanism for regulating protein expression in the nervous system is proposed
by Holt, Prochiantz, and colleagues (Brunet et al., 2005). They show that an external
gradient of the homeodomain transcription factor Engrailed 2 stimulates protein syn-
thesis in the growth cones of retinal axons from Xenopus embryos. This is a new role
for a transcription factor that normally carries out its functions in the nucleus. Using an
in vitro axon turning assay, Brunet and colleagues demonstrate that a gradient of En-
grailed 2 stimulates a change in direction of retinal axons. The authors show that Engrailed is internalized by growth
cones of retinal axons (see the figure) and stimulates local protein synthesis by promoting phosphorylation of pro-
teins involved in translation initiation. By controlling local protein synthesis in the nervous system, Engrailed can
influence axon growth and perhaps also neuronal plasticity.
Brunet et al. (2005). Nature 438, 94-97.
A growth cone of a reti-
nal axon internalizing the
homeodomain transcription
factor Engrailed. (Courtesy
Isabelle Brunet)Cell 123, 717–719, December 2, 2005 ª2005 Elsevier Inc. 717
What Rodents Reveal about Dyslexia
Developmental dyslexia is a common reading disorder that is found in individuals of normal intelligence. Gruen and
colleagues (Meng et al., 2005) now report an association between developmental dyslexia and the gene DCDC2,
which is found in the reading disability locusDYX2 on chromosome 6p22. The protein encoded by this gene is similar
to doublecortin, which is known to interact with and stabilize microtubules in neurons. Mice lacking doublecortin ex-
hibit defects in the migration of cortical neurons during development. Interestingly, anecdotal postmortem analysis
of the brains of dyslexic individuals reveals subtle evidence of attenuated migration of cortical neurons. In their new
work, Gruen and coworkers report that the migration of cortical neurons is attenuated in the brains of embryonic rats
treated with a short-hairpin RNA that binds to DCDC2 RNA. Thus, decreased expression or loss of function of
DCDC2 may result in defects in the migration of cortical neurons that in some as yet unknown way leads to devel-
opmental dyslexia.
Meng et al. (2005). PNAS 102, 17053-17058. Published online November 8, 2005. 10.1073/pnas.0508591102.
A related study suggests that the gene encoding the axonal guidance receptor ROBO1 is also a candidate gene for
developmental dyslexia. Hannula-Jouppi et al. (2005) report that a chromosomal translocation within theDYX5 locus
associated with developmental dyslexia leads to disruption of the ROBO1 gene. The authors found decreased ex-
pression of ROBO1 in affected individuals of a family with developmental dyslexia linked to the DYX5 locus. Could
partial haplo-insufficiency of ROBO1 explain certain rare cases of dyslexia? This is certainly a possibility given that
ROBO1 is involved in the guidance of both dendrites and midline axons during development. Although no neuroan-
atomical or behavioral abnormalities have been reported in Robo1 heterozygous mice, there may be subtle abnor-
malities that have not yet been discovered.
Hannula-Jouppi et al. (2005). PLoS Genetics 1(4), e50.
Seeking Candidate Genes for Schizophrenia
About one-third of individuals carrying a microdeletion of chromosomal region 22q11.2 develop schizophrenia or
a related psychotic disorder. Microdeletion of 22q11.2 results in loss of one copy each of the COMT and PRODH
genes, both of which are candidate susceptibility genes for schizophrenia. COMT encodes a catechol-O-methyl-
transferase that is important for dopamine metabolism, whereas PRODH encodes a mitochondrial proline dehydro-
genase that regulates production of L-proline, a putative neuromodulator. In their longitudinal study, Reiss and col-
leagues (Gothelf et al., 2005) tracked prefrontal cortex volume, cognitive decline, and psychotic behavior from
childhood to late adolescence in individuals carrying the 22q11.2 microdeletion. Their study suggests that one of
the genetic factors determining severity of the disorder is the particular variant of COMT that the individual carries.
There are two COMT variants that differ by one amino acid (COMTH activity is higher than COMTL activity). The au-
thors found that individuals carrying one copy of the COMTL variant showed greater cognitive decline and psychotic
behavior than those carrying one copy of the COMTH variant. Thus, COMT may provide a valuable biomarker for
disease severity in 22q11.2 deletion syndrome and schizophrenia.
Gothelf et al. (2005). Nat. Neurosci. Published online October 23, 2005. 10.1038/nn1572.
In a complementary paper, Karayiorgou, Gogos, and colleagues (Paterlini et al., 2005) analyze mice carrying a mu-
tation in the Prodh gene that leads to a reduction in Prodh activity. These mice exhibit a phenotype reminiscent of
schizophrenia in humans, including hypersensitivity of cortical
neurons to dopamine, learning abnormalities, and an altered re-
sponse to psychomimetic drugs. The authors studied changes
in gene expression in the frontal cortex of the Prodh-deficient
mice by transcriptional profiling. One of the genes upregulated
in these mutant mice wasComt (see the figure). The authors pro-
pose that upregulation of Comt in the frontal cortex might
counter the dopamine hypersensitivity of these mutant mice.
How these tantalizing findings in mice relate to schizophrenia
in humans remains unclear, although rare variants of PRODH
leading to a decrease in enzyme activity have been reported in
individuals with schizophrenia.
Paterlini et al. (2005). Nat. Neurosci. Published online October
23, 2005. 10.1038/nn1562.
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